A Seeking Alpha contributor noted that the clinical trial hold on Geron Corp.'s (Nasdaq: GERN) Imetelstat was temporary. Shares of the biopharmaceutical surged 61 cents to $2.39.
Clinical Trial Hold On Geron's Imetelstat Is Temporary
March 18, 2014 at 13:00 PM EDT
